Abstract
Long-acting bronchodilators are central for treatment of COPD. This short review provides an overview of studies evaluating the efficacy of aclidinium bromide, a long-acting anticholinergic bronchodilator, for the treatment of COPD. Twice-daily dosing of aclidinium leads to clinically important improvements in forced expiratory volume in 1 second, health status, use of rescue medication, day-time dyspnoea and exercise tolerance. The available studies also suggest an effect on night-time dyspnoea and exacerbation rate in patients with COPD. Aclidinium seems to have potential for a significant role in the future management of COPD.
| Translated title of the contribution | Aclidinium bromide improves the lung function and reduces dyspnoea in patients with COPD. |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 176 |
| Issue number | 28 |
| Pages (from-to) | 1296-1299 |
| Number of pages | 4 |
| ISSN | 0041-5782 |
| Publication status | Published - 7 Jul 2014 |